Sign Out
Because Pregabalin is not bound to plasma proteins, a pharmacokinetic interaction with drugs that are highly protein bound is unlikely.
Concomitant use of Pregabalin and angiotensin-converting enzyme inhibitors (ACEI) may increase the risk of developing angioedema.
Concomitant use of Pregabalin and CNS depressants (e.g. ethanol, lorazepam, oxycodone) may lead to an additive effect in the impairment of cognitive and gross motor function. No clinically important effects on respiration have been noted.
Concomitant use of Pregabalin and thiazolidinedione antidiabetic agents may increase the risk of edema, weight gain and/or fluid retention. Use with caution.
Concomitant use of Pregabalin and anticonvulsants (e.g. phenytoin, carbamazepine, valproate, lamotrigine, phenobarbital, topiramate) is unlikely to lead to pharmacokinetic interactions.
